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Abstract
Mammalian Toll-like receptors (TLRs) 3, 7, 8 and 9 initiate immune responses to infection by 
recognizing microbial nucleic acids1, 2; however, these responses come at the cost of potential 
autoimmunity due to inappropriate recognition of self nucleic acid3. The localization of TLR9 and 
TLR7 to intracellular compartments appears to play a role in facilitating responses to viral nucleic 
acids while maintaining tolerance to self nucleic acid, yet the cell biology regulating the 
trafficking and localization of these receptors remains poorly understood4-6. Here, we define the 
route by which TLR9 and TLR7 exit the endoplasmic reticulum (ER) and traffic to 
endolysosomes. Surprisingly, the ectodomains of TLR9 and TLR7 are cleaved in the 
endolysosome, such that no full-length protein is detectable in the compartment where ligand is 
recognized. Remarkably, though both the full-length and cleaved forms of TLR9 are capable of 
binding ligand, only the processed form recruits MyD88 upon activation, arguing that this 
truncated receptor, rather than the full-length form, is functional. Furthermore, conditions that 
prevent receptor proteolysis, including forced TLR9 surface localization, render the receptor non-
functional. We propose that ectodomain cleavage represents a strategy to restrict receptor 
activation to endolysosomal compartments and prevent TLRs from responding to self nucleic acid.
The sub-cellular localization of TLR9 and TLR7 is highly regulated. While ligand 
recognition occurs in endolysosomes, it has been reported that most, if not all, TLR9 resides 
in the ER of resting cells5, 6. Curiously, analyses of N-linked glycosylation on TLR9 
indicates that the protein does not traffic through the Golgi, even in activated cells5, 6. 
These observations have led to a model in which TLR9 is recruited directly to 
endolysosomes from the ER, bypassing the classical secretory pathway5. However, general 
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mechanistic details accounting for such unusual cell biology are lacking, and the specific 
details of how TLR9 transport is regulated between these compartments remain largely 
unknown.
In order to separate ER-resident TLR9 from receptors in the endolysosome, we purified 
phagosomes from cells fed latex beads. To track TLR9, we used macrophage-like RAW264 
cells stably expressing TLR9 with a C-terminal HA tag (RAW-TLR9 cells). We have 
previously shown that this epitope tag does not affect TLR9 function4. As expected, 
phagosome preparations were enriched for the lysosomal protein Lamp-1 while devoid of 
markers of other intracellular organelles and the cytosol (Fig. 1a). Surprisingly, we did not 
observe any TLR9 at the expected molecular weight, 150 kilodaltons (kDa). Instead, an 
approximately 80 kDa protein was highly enriched in the phagosomal preparation (Fig. 1a). 
The presence of ligand did not alter receptor translocation, as we could not detect full-length 
TLR9 in phagosomes containing latex beads coated with CpG oligos (Fig. 1b), despite the 
fact that these beads induced TLR9 signalling (Sup. Fig. 1a). In contrast, the 80 kDa protein 
was evident in phagosomes at the earliest timepoint examined (10 minutes) and remained 
equally abundant over 4 hours (Fig. 1b).
To demonstrate directly that the 80 kDa band in our phagosome preparations represented a 
cleaved form of TLR9, we performed pulse-chase analysis. The 80 kDa band was first 
detectable after 3 hours of chase, concomitant with the onset of full length receptor 
degradation (Fig. 1c). The 80 kDa band continued to accumulate in parallel with the 
degradation of full-length TLR9, peaking at 6 hours when the full-length protein was no 
longer detectable. These data formally demonstrate that the 80 kDa protein is a cleavage 
product of full-length TLR9 consisting of approximately half of the ectodomain, the 
transmembrane domain, and the entire cytoplasmic domain. Based on molecular weight, we 
estimate that cleavage occurs within or distal to leucine rich repeat (LRR) 14. Structural 
modelling of TLR9 suggests that the cleaved receptor adopts an abbreviated ”horseshoe” 
fold encompassing a region that corresponds to residues implicated in ligand-binding by 
TLR37, 8 (Fig. 1d). A C-terminal cleavage product of TLR9 was also present in M-CSF 
derived macrophages, GM-CSF derived DCs, and Flt3L-derived plasmacytoid DCs, 
indicating that similar processing events occur in many immunologically relevant cell types 
(Fig. 1e). We observed a similar cleavage product of TLR7, but not of TLR4, suggesting 
that receptor processing may be a general feature shared by nucleic acid sensing TLRs (Fig. 
1f).
We next sought to determine where within the cell TLR9 cleavage occurs. While N-linked 
sugars on full-length TLR9 were sensitive to endoglycosidaseH (EndoH), the majority of the 
sugars on the cleaved form of TLR9 were resistant to EndoH, indicating that the truncated 
form of the receptor has passed through the Golgi (Fig. 2a). A similar glycosylation pattern 
was observed for TLR7 (Sup. Fig. 1b). In addition, a small fraction of full-length TLR9 
consistently migrated slightly slower than the majority of the full-length protein (Fig. 2b, see 
asterisk). Interestingly, this high molecular weight band was almost entirely EndoH-
resistant, in contrast to the rest of the full-length TLR9 protein, indicating that this small 
pool of full-length protein has also passed through the Golgi. We also observed this high 
molecular weight, EndoH-resistant band in pulse/chase experiments (asterisks in Fig. 1c & 
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Sup. Fig. 1c). The band appeared after 1½ hours of chase, immediately preceding formation 
of the cleavage product. Furthermore, the intensity of the high molecular weight band 
appeared to match the intensity of the accumulated cleavage product. Collectively, these 
data suggest that this high molecular weight band represents the small fraction of TLR9 that 
exits the ER, passes through the Golgi, and is cleaved. In support of this model, cells treated 
with brefeldin A (BFA), a reagent that disrupts the Golgi, contained neither the high 
molecular weight band (1.5h chase) nor the 80 kDa cleavage product (5h chase) (Fig. 2c). 
Analysis of TLR9 localization by immunofluorescence microscopy corroborated our 
biochemical findings (Sup. Figs. 2 & 3).
To address the mechanism responsible for TLR9 sorting from the ER, we examined 
Unc93b19-11. Mice with a deficiency in Unc93b1 no longer respond to TLR3, TLR7 and 
TLR9 ligands11, and Unc93b1 can associate with TLR3, TLR7 and TLR9 which may 
facilitate trafficking to endolysosomes9, 10. We generated RAW cells in which Unc93b1 
mRNA was knocked down by retrovirally-encoded shRNA (Fig. 3a). As expected, these 
cells exhibited reduced TNF-α production in response to CpG and R848 relative to control 
cells (Fig. 3b). Strikingly, the TLR9 cleavage product was greatly reduced in Unc93b1 
knockdown cells, though full-length TLR9 was expressed at levels comparable to control 
cells (Fig. 3c). The high molecular weight, full-length TLR9 band was also absent in 
Unc93b1 knockdown cells (Fig. 3c), and TLR9 was not present in phagosomes purified 
from Unc93b1 knockdown cells (Fig. 3d). These data demonstrate that Unc93b1 is required 
for TLR9 exit from the ER. To test whether Unc93b1 is also sufficient for this exit, we 
overexpressed Unc93b1 in mouse embryonic fibroblasts (MEFs), which signal poorly in 
response to CpG oligos. Whereas we detected very little TLR9 cleavage in control cells, 
simply over-expressing Unc93b in MEF-Unc93b cells resulted in a 75-fold increase in the 
80 kDa band (Fig. 3e). The increase in cleaved TLR9 corresponded with a robust increase in 
responsiveness to CpG oligos (Fig. 3f). Thus, Unc93b1 appears to control the functional 
pool of TLR9 by regulating exit from the ER. Furthermore, the fraction of TLR9 that exits 
the ER and is cleaved appears to be responsible for TLR9 signalling.
We next attempted to block TLR9 cleavage by inhibiting various cellular proteases. 
BafilomycinA1, an inhibitor of the vacuolar ATPase, blocks endolysosomal acidification as 
well as signalling by TLR9, TLR7, and TLR312. Pulse/chase analysis of RAW-TLR9 cells 
treated with bafilomycinA1 revealed TLR9 cleavage was completely blocked when 
endolysosomal acidification was inhibited (Fig. 4a). Blocking TLR9 proteolysis with 
baflomycinA1 also resulted in a 20-fold accumulation of the high molecular weight TLR9 
species, further supporting the idea that this band is the precursor to the cleavage product.
Two recent reports have shown that inhibitors of cathepsin K (CtsK) and cathepsin B (CtsB) 
block TLR9 signal transduction in DCs and macrophages, respectively13, 14. To address 
whether specific cathepsins may be involved in TLR9 processing, we tested whether 
recombinant cathepsins could cleave TLR9 in vitro. We observed that recombinant CtsK 
and CtsS could cleave full-length TLR9 in vitro to generate an approximately 80 kDa 
cleavage product (Fig. 4b). While these experiments implicate cathepsin family members in 
TLR9 processing, we were unable to block processing using cathepsin inhibitors. Pulse/
chase analysis showed that the cleaved form of TLR9 was still present in RAW-TLR9 cells 
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treated with the broad spectrum inhibitors E64d, pepstatinA, and leupeptin as well as with 
specific inhibitors of CtsK, CtsB, and CtsS (Sup. Fig. 4). With the exception of a CtsB 
inhibitor, these compounds did not affect TLR9 signalling (Sup. Fig 4 and data not shown). 
Finally, we observed no defect in TLR9 signalling in macrophages and DCs from CtsS-, 
CtsSxL-, CtsK-, and CtsB-deficient mice (Sup. Fig. 5). Notably, these results disagree with 
recent work implicating CtsK and CtsB in TLR9 function13, 14, though these works relied 
heavily on protease inhibitors which may have off-target effects. Instead, our data suggest 
that none of these proteases are solely responsible for cleaving TLR9 and are consistent with 
an interpretation that multiple proteases are capable of processing the receptor.
The results described above strongly implicate proteolysis as a step required for TLR9 
function, but they do not directly demonstrate that processed TLR9 is a functional receptor. 
To address this possibility, we tested whether the cleaved form of TLR9 can bind 
stimulatory CpG oligos. We found that TLR9 purified from phagosomes and incubated with 
biotinylated-CpG oligos could be efficiently precipitated using streptavidin beads (Fig. 4c). 
Thus, this processed form of TLR9, which is exclusively in the phagosome, is capable of 
recognizing ligand. We next compared CpG-binding between the full-length and cleaved 
forms of TLR9. The truncated receptor was pulled down more efficiently than full-length, 
suggesting that it may have a higher affinity for ligand (Fig 4d). This interaction was 
specific, as binding was disrupted by addition of non-biotinylated CpG oligo (Fig. 4d).
Since both full-length and processed TLR9 can bind ligand, we sought to determine which 
form is responsible for signal transduction. The adaptor MyD88 associates with TLR9 after 
activation, so we examined which form of the receptor recruits MyD88 in response to CpG 
stimulation. Remarkably, immunoprecipitation of MyD88 in activated cells pulled down 
only the processed form of TLR9 (Fig. 4e). We were unable to detect any association 
between MyD88 and the full-length receptor, demonstrating that the processed form of 
TLR9 is the functional form of the receptor. We next hypothesized that requiring proteolysis 
may reduce the likelihood that functional receptors will leak to the cell surface and 
encounter self nucleic acid. To test this possibility, we used a recently reported strategy of 
fusing Unc93b1 to a yeast protein domain, Ist2, that directs trafficking of both Unc93b1 and 
TLR9 to the plasma membrane10. While Unc93b1-Ist2 localized to the plasma membrane 
(Sup. Fig. 6a), we did not observe significantly altered TLR9 processing or signalling in 
Unc93b1-Ist2 expressing cells (Fig. 4f & Sup. Fig. 6b). These results suggest that a 
significant portion of TLR9 may avoid relocalization in Unc93b1-Ist2 cells and signal from 
internal compartments. Thus, we fused TLR9 directly to the Ist2 secretion sequence and 
examined the signalling and localization of this fusion protein. Consistent with 
relocalization of the receptor to the cell surface, endoH analysis indicated that the TLR9-Ist2 
fusion protein passed through the Golgi but remained unprocessed (Fig. 4g. Remarkably, 
TLR9-Ist2 no longer responded to CpG oligos (Fig. 4h). To ensure that this lack of 
signalling was not due to the Ist2 domain simply interfering with the TLR9 TIR domain, we 
generated a TLR9-Ist2 fusion protein in which the key amino acids necessary for plasma 
membrane targeting have been deleted (TLR9-Ist2δ18)15. This receptor was processed (Fig. 
4g) and regained the ability to respond to CpG oligos (Fig. 4h), despite the presence of the 
non-functional Ist2 domain at its C-terminus.
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Our results reveal that compartmentalized proteolysis of TLR9 represents a key step in 
nucleic acid recognition. Though both full-length and processed forms of the receptor can 
bind ligand, only the cleaved form of TLR9 is competent for signal transduction. It remains 
unclear why processing is necessary for TLR9 activation. In a previous study we showed 
that a surface localized chimeric receptor TLR9N4C (consisting of the TLR9 ectodomain 
and TLR4 TM and cytosolic domains) was hyperresponsive to self DNA4. Unlike TLR9-
Ist2, this receptor signals from the cell surface even when fused to Ist2 but is not processed 
(Fig. 4h lower panel and Ref 4). Swapping the transmembrane (TM) and cytosolic domains 
of TLR9 for those of TLR4 has apparently released this receptor from the processing 
requirement. Recent work suggests that TLR9 undergoes a membrane-proximal 
conformational change upon ligand binding and activation16. One possibility is that TLR9 
cleavage is a prerequisite for this conformational change. This regulatory mechanism may 
not be required for cell surface receptors like TLR4, explaining the ability of full-length 
TLR9N4C to signal. Analyses comparing the structure and conformational changes of the 
full-length and truncated TLR9 receptors will be necessary to resolve these possibilities.
The proteolytic regulatory step described here is consistent with a model in which TLRs 
involved in nucleic acid sensing are translated as ”pro-receptors” in the ER and only 
function after being processed in the endolysosomal compartment (Fig. 4i). This scenario is 
conceptually analogous to the production of proteases as pro-enzymes that must be 
processed before they gain enzymatic activity. In this way, compartmentalized processing of 
TLR9 may regulate where within the cell TLR9 activation can occur. We and others have 
argued that restricting activation of TLR9 and TLR7 to intracellular compartments may limit 
responses to self nucleic acid while preserving the ability to recognize foreign nucleic acid4, 
17, 18. Thus, the requirement for processing of TLR9 and TLR7 may represent an 
evolutionary strategy to ensure proper self/non-self discrimination based on nucleic acid 
recognition.
Methods Summary
Detailed descriptions of reagents and experiments can be found in Supplementary Methods. 
All stable cell lines were generated by retroviral gene transfer. For phagosome isolation, 
RAW cells were fed latex beads (Polysciences), the cells were disrupted by Dounce 
homogenization, and latex bead containing phagosomes were purified on a 62%−10% 
sucrose step gradient in a Beckman SW40Ti centrifuge. After purification, phagosomes 
were lysed by addition of TritonX-100, and proteins in phagosomes were separated by SDS-
PAGE and visualized by immunoblot. Pulse/chase analyses were performed by starving 
cells of cysteine/methionine for 1 hour, pulsing with 35S-cysteine/methionine for 45 
minutes, and chasing in molar excess of unlabeled cysteine/methionine for the indicated 
time periods. After lysis, radiolabeled proteins were immunoprecipated and visualized by 
SDS-PAGE. Deglycosylation assays were performed on immunoprecipitated proteins using 
endoglycosidaseH or PNGaseF (both from NEB) with supplied buffers according to 
manufacturer's instructions. Proteins were separated by SDS-PAGE and visualized by 
immunoblot. In vitro proteolysis with recombinant cathepsins (Biomol) was performed 
according to manufacturer guidelines. For MyD88/TLR9 coimmunoprecipitations, cells 
were lysed in RIPA Buffer before or after stimulation with CpG, and protein complexes 
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were precipitated with anti-FLAG matrix. For CpG binding assays, TLR9-HA containing 
lysates were incubated with Biotin-CpG followed by precipitation with streptavidin matrix. 
In both cases, precipitated proteins were visualized by SDS-PAGE followed by immunoblot. 
NF-κB luciferase assays were performed by transient transfection of HEK293T cells with an 
NF-κB luciferase reporter plasmid and the indicated expression plasmids using LTX 
transfection reagent (Invitrogen) according to manufacturer's instructions. C57/Bl/6 mice 
were purchased from Jackson Laboratories. All knockout mice have been previously 
described19-22. Mice were housed within animal facilities at UC Berkeley or UCSF 
according to IACUC guidelines.
Methods
Reagents
All chemicals and reagents, unless noted otherwise, were purchased from Fisher Scientific. 
Anti-HA (Clone 3F10) and anti-FLAG (M2) affinity matrices were purchased from Roche 
and Sigma, respectively. Latex beads were purchased from Polysciences. CpG 
oligonucleotides (TCCATGACGTTCCTGACGTT) with phosophorothioate linkages and 
5’-biotinylated CpG oligos (of the same sequence) were purchased from Invitrogen and IDT. 
LPS, R848, BLP and biotinylated LPS were purchased from Invivogen. All antibodies for 
flow cytometry and ELISAs were purchased from eBioscience. The following antibodies 
were used for immunoblotting: anti-HA (Roche), anti-FLAG M2 (Sigma), anti-calnexin 
(Stressgen), anti-HSP90B (Thermo Scientific), anti-Lamp1 (Santa Cruz), anti-tubulin 
(EMD), anti-nuclear pore complex (Covance), goat anti-rat-HRP and sheep anti-mouse HRP 
(GE Amersham).
Mice
C57Bl/6 and 129Sv mice were purchased from Jackson Laboratories. 
TLR2−/−xTLR4−/−xTLR9−/− mice were generated by intercrossing individual knockout 
mice, kindly provided by Dr. S. Akira (Osaka University). CtsK−/−21, CtsS−/−22, and 
CtsSxL−/−20 mice (all backcrossed to C57Bl/6) and CtsB−/−19 mice (on the 129Sv 
background) have been previously described. All mice were housed within the animal 
facilities at the University of California at Berkeley or University of California at San 
Francisco according to IACUC guidelines.
Cell lines, plasmids, and tissue culture
RAW264 cells were purchased from ATCC and cultured in RPMI supplemented with 10% 
FCS, L-glutamine, penicillin/streptomycin, sodium pyruvate, and HEPES (all from 
Invitrogen). Unless otherwise noted, stable lines were generated by transducing cells with 
MSCV2.2 retroviruses encoding the target cDNA. For RAW-TLR9, RAW-TLR7 and 
RAWTLR4 cells, cDNA encoding the HA epitope was inserted at the 3’ end of each TLR. 
FLAG-TLR9 and FLAG-MyD88 have been previously described23. Unc93b-Ist2 was 
constructed as previously described10. TLR9-Ist2 and TLR9N4C-Ist2 were made by fusing 
the 69-residue Ist2 tag to the 3’ end of TLR9-HA or TLR9N4C-HA, respectively.
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Bone marrow-derived conventional DCs (cDCs), macrophages, and plasmacytoid DCs 
(pDCs) were differentiated, as previously described4, in RPMI supplemented with GM-CSF 
containing supernatant, M-CSF containing supernatant, or 25ng/ml recombinant Flt3L 
(R&D), respectively. To generate cDCs and pDCs expressing TLR9-HA, hematopoetic stem 
cells (HSCs) from TLR2−/−xTLR4−/−xTLR9−/− mice were transduced with retroviruses 
encoding TLR9-HA as previously described4. Briefly, mice were injected with 5-
flourouracil (Sigma) to enrich for HSCs. HSCs were cultured in IL-6, IL-3 and SCF (all 
from R&D) over 4 days and transduced with retroviruses. After 5 days, HSCs were 
differentiated into cDCs or pDCs as described above.
Splenic DCs were isolated from C57Bl/6 or CtsK−/− mice by magnetic cell sorting using 
anti-CD11c conjugated magnetic beads (Miltenyi Biotech) and an AutoMACS cell sorter 
(Miltenyi Biotech). Enrichment, as measured by FACS, was greater than 70%.
Immunoprecipitation and Western blot analyses
Cells were lysed in RIPA buffer (50mM Tris pH 8, 150mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS) supplemented with Complete protease inhibitor cocktail (Roche). 
After incubation on ice, lysates were cleared of insoluble material by centrifugation. For 
immunoprecipitations, lysates were incubated with anti-HA matrix or anti-FLAG matrix and 
precipitated proteins were separated by SDS-PAGE and transferred to Immobilon PVDF 
membrane (Millipore). Membranes were probed with the indicated antibodies and developed 
by ECL chemiluminescence (Pierce). Relative band intensities were quantified by counting 
pixels per band using ImageJ software.
Steptavidin pull-downs were performed on cells or purified phagosomes lysed in TNT 
buffer (20mM Tris pH 8.0, 200mM NaCl, 1% Triton X-100) and cleared of insoluble debris. 
Lysates were incubated for 1h with 0.2μM biotin-CpG and/or unlabeled CpG on ice, added 
to streptavidin-agarose (Invitrogen, pre-blocked with 1% BSA-PBS), rotated 1h at 4°C, and 
washed 4 times in lysis buffer. Precipitates were boiled in SDS buffer, separated by SDS-
PAGE, and probed by anti-HA immunoblot.
Microscopy
Co-localization studies were performed on a Zeiss 510 Axioplane META microscope. 
Coverslips were coated with poly-D-lysine (Sigma), washed extensively with water and 
allowed to dry (1h). Cells were allowed to settle overnight. The next day, coverslips were 
washed with PBS, fixed with 4% PFA/PBS, and permeabilized with 0.5% Triton-X/PBS. 
After washing with 0.1% Triton-X/PBS, cells were blocked (5% goat sera, 2% BSA, 0.1% 
sodium azide, 0.1% Triton-X/PBS). Slides were stained in blocking buffer with anti-FLAG, 
anti-HA, anti-calnexin or anti-Lamp (see antibodies used for western blot). Secondary 
antibodies were donkey anti-rabbit Cy5, donkey anti-rabbit Cy3, goat anti-rat Cy3, goat anti-
mouse Cy3 (Jackson) or donkey anti-rat Alexa680 (Invitrogen).
Visualization of Unc93b1-GFP and Unc93b1-GFP-Ist2 was performed on a Nikon E800 
fluorescent microscope. Cells were plated and fixed as described above.
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Transient transfections were performed in OptiMem (Invitrogen) with LTX transfection 
reagent (Invitrogen) according to manufacturer's guidelines. 293T cells were transiently co-
transfected with the indicated expression plasmid(s) and a plasmid encoding an NF-κB 
luciferase reporter (with 5 tandem NF-κB binding sites, kindly provided by Russell Vance). 
Cells were stimulated with 3μM CpG oligo after 24 hours and lysed by passive lysis after an 
additional 12 hours. Luciferase activity was measured on a LMaxII-384 luminometer 
(Molecular Devices).
Pulse/chase
Cells were starved for 1h in cysteine/methionine-free media, then pulsed with 0.1mCi 35S-
cysteine/methionine (Perkin-Elmer). After a 45 minute pulse, cells were washed and 
cultured in 5mL chase media with 10,000-fold molar excess L-cysteine, L-methionine or 
harvested as the zero timepoint. Time points were harvested as follows: cells were washed 
twice in 2mL PBS and lysed in 1mL RIPA plus protease inhibitor cocktail. For protease 
inhibitor experiments, inhibitors were added in chase media and supplemented every two 
hours at the following concentrations: 50μM E64d (EMD); 100μM pepstatin A (Sigma); 
100μM leupeptin (Sigma); 10nM cathepsin K inhibitor III (Cbz-Leu-NH-CH2-CO-CH2-NH-
Leu-Cbz, Sigma); 30μM CtsB inhibitor (Me047, EMD); 2μM CtsS inhibitor (-Phe-Leu-
COCHO • H2O, EMD). BaflomycinA1 (Sigma) was used at 50nM and BrefeldinA (Sigma) 
was used at 10μg/mL.
Phagosome isolation
4x107 RAW cells were incubated with ∼108 2μM latex beads (Polysciences) for various 
time points. After rigorous washing in PBS, RAW cells were scraped into 3ml sucrose 
homogenization buffer (SHB: 250μM sucrose, 3mM imidazole pH7.4) and pelleted by 
centrifugation. Cells were resuspended in 1mL SHB plus protease inhibitor cocktail (Roche) 
and EDTA and disrupted by 25 strokes in a steel dounce homogenizer. The disrupted cells 
were gently rocked for 10 minutes on ice and centrifuged at 8,000xg to remove intact cells, 
nuclei and gross debris. The remaining supernatant was further processed to separate intact 
phagosomes. 40μL was set aside as the ”lysate” sample and lysed by addition of 1% 
TritonX-100. The remaining supernatant was mixed with an equal volume of 60% sucrose, 
and applied to a sucrose step gradient as follows: 1mL 60% sucrose, 2mL homogenate, 2mL 
32% sucrose, 2mL 20% sucrose, 2mL 10% sucrose. The gradient was spun at 100,000xg for 
1h in a SW40 rotor. Following centrifugation, phagosomes were harvested from the 
20%-10% sucrose interface. Phagosomes were diluted in 10mL PBS and spun at 40,000xg 
for 15 minutes in an SW40 rotor. The phagosome pellet was resuspended in 40μL SHB, 
protease inhibitor cocktail, EDTA and 1% TritonX-100. Protein concentrations were 
normalized by BCA assay, and lysates were analysed by western blot.
In vitro proteolysis assay
Recombinant cathepsin S and recombinant pro-cathepsin K were purchased from BioMol. 
293T cells stably expressing TLR9-HA were lysed in RIPA buffer and TLR9 was 
immunoprecipitated with anti-HA agarose. Immunoprecipitates were washed 4 times in 
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cathepsin reaction buffer (50mM potassium phosphate pH 6.5, 50mM NaCl, 2mM EDTA, 
0.01% TritonX-100, 0.5mM DTT) followed by incubation with or without cathepsins. Pro-
cathepsin K was activated according to manufacturer's instructions (i.e., incubation in 
32.5mM NaOAc pH3.5 for 25 minutes at 24 degrees). Activated cathepsin K was 
immediately incubated with immunoprecipitated TLR9-HA in cathepsin reaction buffer for 
45 minutes at 24°C. Cathepsin S (0.0024 units) was added directly to immunoprecipitated 
TLR9-HA in cathepsin reaction buffer and incubated for 45 minutes at 40°C. Enzymes were 
inactivated by the addition of SDS loading buffer and boiling. Reactions were resolved by 
SDS-PAGE and anti-HA immunoblot (as described above).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. A truncated version of TLR9 is exclusively present in phagosomes
(a) Lysates or phagosome preparations from RAW-TLR9 cells fed latex beads were 
separated by SDS-PAGE and probed with antibodies specific for the indicated proteins. 
Full-length TLR9 (FL TLR9) and the truncated protein (cleaved TLR9) are indicated. (b) 
Analysis of phagosomes from RAW-TLR9 cells fed unconjugated latex beads or beads 
conjugated to stimulatory CpG oligos. Lysates or purified phagosomes from the cells were 
separated by SDS-PAGE and probed with antibodies against the indicated proteins. (c) The 
truncated form of TLR9 is a product of the full-length protein. Pulse/chase analysis of 
RAW-TLR9 cells or control cells (RAW). Asterisk (*) indicates the high molecular weight 
full-length TLR9 band. ”NS” indicates a non-specific band present in both RAW-TLR9 and 
control RAW cells. (d) Modelled structure of the truncated ectodomain (residues 477−790) 
of TLR9. Leucine rich repeats (LRR) 15 − 26 are labelled. (e) The TLR9 cleavage product is 
present in multiple cell types. Hematopoetic stem cells were transduced with a retrovirus 
encoding TLR9-HA and then differentiated into macrophages with M-CSF (MØ), dendritic 
cells with GM-CSF (cDC), or plasmacytoid dendritic cells with Flt3L (pDC). (f) Lysates 
from RAW cells expressing TLR4-HA or TLR7-HA were probed with anti-HA antibody. 
Note that TLR4 is not cleaved. The two bands of TLR4 are due to glycosylation. Note: 
unless indicated otherwise, the data presented in each panel are representative of at least 3 
independent experiments.
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Figure 2. Prior to cleavage, TLR9 exits the ER and traffics through the Golgi
(a) Cleaved TLR9 is EndoH-resistant. Proteins from lysates or purified phagosomes from 
RAW-TLR9 cells were immunoprecipitated with anti-HA resin and treated with EndoH (E), 
PNGaseF (P), or left untreated (-). (b) A longer exposure of TLR9 immunoprecipated from 
RAW-TLR9 cells and subjected to analysis as described in (a). An asterisk (*) indicates the 
high molecular weight full-length TLR9 band that is EndoH-resistant. (c) TLR9 cleavage 
requires passage through the Golgi. Pulse/chase analysis was performed, at the indicated 
chase time points, on RAW-TLR9 cells treated with brefeldinA (B) or vehicle (—). Note: 
the data presented in each panel are representative of at least 3 experiments.
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Figure 3. Unc93b1 is required for TLR9 ER exit and cleavage
(a) Expression of Unc93b1 transcript was measured by quantitative RT-PCR in RAW cells 
transduced with a control retrovirus or a retrovirus encoding an shRNA specific for 
Unc93b1. (b) Unc93b1-shRNA RAW cells respond poorly to TLR7 and TLR9 ligands but 
not TLR4 ligands. RAW cells or Unc93b1-shRNA RAW cells were stimulated with the 
indicated ligands and TNFα production was measured by ELISA (representative of two 
experiments). (c) Unc93b1 is required for TLR9 cleavage. Lysates from control RAW-TLR9 
cells (vector) or RAW-TLR9 cells transduced with the Unc93b1 shRNA retrovirus (Unc. 
shRNA) were probed with anti-HA antibodies or anti-tubulin antibodies. (d) Lysates or 
purified phagosomes from the same cells described in (c) were analyzed for the presence of 
TLR9 by anti-HA immunoblot. (e) Overexpression of Unc93b1 in MEFs enhances TLR9 
cleavage. TLR9 in lysates of MEFs stably expressing TLR9-HA or TLR9-HA with Unc93b1 
was detected by anti-HA immunoblot. RAW-TLR9 cells were included as a control for 
TLR9 cleavage product. (f) Cells described in (e) were stimulated with 5μM CpG or 
25ng/mL recombinant mouse IL-1β. KC production was measured by ELISA (representative 
of 2 experiments). Unless noted otherwise, all data presented are representative of at least 3 
experiments. For indicated statistical comparisons, * indicates p<0.05; ** indicates p<0.01.
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Figure 4. Processing of TLR9 is necessary to generate a functional receptor
(a) TLR9 cleavage requires the activity of acid-dependent proteases. Pulse/chase analysis 
was performed on RAW-TLR9 cells treated with 50nM bafilomycinA1 (Baf) or DMSO (-) 
vehicle control. (b) In vitro proteolysis assay performed on TLR9-HA immunoprecipitated 
from 293T cells. TLR9-HA was incubated with recombinant CtsK, CtsS or no cathepsin 
(—) and detected by anti-HA immunoblot. (c) The cleaved form of TLR9 can bind ligand. 
(Left) Whole cell lysates or lysates of purified phagosomes were immunoprecipitated with 
anti-HA antibody, separated by SDS-PAGE and immunoblotted with anti-HA antibody. 
(Right) Lysates of purified phagosomes were incubated with (+) or without (—) 0.2 μM 
Biotin-CpG followed by steptavidin precipitation. TLR9-HA was detected by anti-HA 
immunoblot. Data are representative of two experiments. (d) Cell lysates were incubated 
with (+) or without (-) Biotin-CpG and precipitated with streptavidin as described in (c). 
Where indicated, unconjugated CpG was also added, prior to precipitation. Unmanipulated 
lysate (No IP) is shown as a control. (e) Cleaved TLR9 recruits MyD88. RAW cells 
expressing TLR9-HA and FLAG-MyD88 were stimulated with CpG oligos followed by 
lysis at the indicated time points. After lysis, MyD88 was immunoprecipitated and TLR9 or 
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MyD88 were detected by anti-HA or anti-FLAG immounoblot, respectively. (f) TLR9 does 
not signal from the cell surface in Unc93b1-Ist2 cells. 293T cells were transiently 
transfected with an NF-κB luciferase reporter together with the indicated expression 
plasmids. Luciferase production was assayed 12h after stimulation with 3μM CpG, with or 
without pre-treatment with 50μM chloroquine (CHQ). (g) TLR9, TLR9-Ist2, and TLR9-
Ist2δ18 expressed in RAW cells were analyzed for sensitivity to EndoH or PNGaseF as 
described in Fig. 2a. (h) 293T cells were transiently transfected with the indicated 
expression plasmids and NF-κB activation was measured as described in (f). (i) Schematic 
of compartmentalized proteolysis and regulation of TLR9 and TLR7. Note: for indicated 
statistical comparisons, * indicates p<0.05; ** indicates p<0.1. Unless noted otherwise, all 
data presented are representative of at least 3 independent experiments.
Ewald et al. Page 15
Nature. Author manuscript; available in PMC 2009 June 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
